Extending its rally for the second straight session today, shares of Claris Lifesciences surged 8 per cent, after the company received the Establishment Inspection Report (EIR) from the US health regulator for its manufacturing plant near Ahmedabad.
Shares of the company jumped 8.07 per cent to settle at Rs 218.20 on BSE. During the day, it surged 16.34 per cent to Rs 234.90.
The stock had gained 20 per cent in the previous session also.
Claris Lifesciences has "received the EIR for its manufacturing facility located near Ahmedabad, wherein the US Food and Drug Administration (USFDA) has concluded that the inspection stands closed and the facility was found to be acceptable," Claris Lifesciences said in a filing to BSE yesterday.
The USFDA had conducted audit at Claris' manufacturing facility in May, 2015, it added.
"The company had taken appropriate steps to address the observations it had received from these audits," Claris said.
Having received the EIR from the USFDA potentially clears the path for the company to receive product approvals (ANDA) for the USA, it added.
